Innogenetics concludes settlement and licensing agreement in the field of Hepatitis C diagnostics
Hepatitis C immunodiagnostics is key for the detection and confirmation of Hepatitis C Virus. At present the technique is routinely used in clinical diagnostics and serology.
At the end of 1998, Innogenetics was subject to descriptive and seizure proceedings based on the allegation that the Company would be infringing two European patents relating to HCV. The action was originally lodged by Chiron, which has been acquired by Novartis in 2006. The present agreements terminate the actions and provide Innogenetics the rights to remain commercially active in HCV immunodiagnostics in those territories where it has a business interest.
No financial details were disclosed.
Topics
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.